Piyasa açık· · GBp · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Financing co-led by Heal Capital and Ananda Impact Ventures will advance the Aitios® platform and ongoing validation of lead program to identify preeclampsia risk in a pregnancy’s first trimesterDr. Gordon Sanghera CBE FRS, co-founder and former CEO of Oxford Nanopore Technologies, joins Aitiologic’s advisory board and participates in the round as an investorDr. Rebecca Ertl, obstetrician-gynecologist and founder of a leading prenatal diagnostics center, appointed Chief Medical Officer VIENNA, S
The global transcriptome sequencing market is projected to reach $11.8 billion by 2035, growing at a 7.3% CAGR from 2025 to 2035. Growth is driven by falling sequencing costs, precision medicine, drug discovery, biomarker development, single-cell and spatial transcriptomics, long-read RNA sequencing, and AI-powered analytics. Consumables, bulk RNA-seq, drug discovery applications, and pharmaceutical and biotechnology companies led the market in 2025. North America held the largest regional share
Oxford Nanopore Technologies (LON:ONT) reported first-half revenue growth below its expectations as declines in China, the Middle East and delayed orders in the Americas weighed on performance, while gross-margin expansion and lower operating expenses narrowed its adjusted EBITDA loss. Revenue for
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.